The State of Alzheimer’s Disease: Focus and Funding

This past year we at Nelsen Biomedical completed a large landscape analysis of Alzheimer’s disease. We interviewed leaders in industry, the investment community, foundations and non-profits in addition to clinicians and scientists. We identified key barriers to progress and novel scientific and clinical areas for focus and funding.

With the 2019 Q1 failures of Roche and Biogen/Eisai’s Phase III trials, it is time to share some key points on where the field is headed and what this means for both patients and the industry.

For the full report, contact us at info@nelsenbiomedical.com

Free download

Overview PDF, 3MB